New Laser Treatment May Stop Blindness Before It Starts

Imagine if doctors could stop blindness before it even begins. That's exactly what researchers at Aalto University in Finland are working toward with a breakthrough treatment for dry age-related macular degeneration, one of the leading causes of blindness worldwide.

The condition affects roughly one third of people over 80 and about 20 million Americans over age 40. It slowly damages central vision, making everyday tasks like reading, driving, or recognizing faces increasingly difficult. Until now, doctors have had few options to stop the disease early, before serious damage occurs.

The new approach uses carefully controlled near-infrared light to gently warm tissue at the back of the eye by just a few degrees. This mild heat acts like a wake-up call for aging cells, triggering their natural repair and cleanup systems before major damage sets in.

Professor Ari Koskelainen explains that as we age, our cellular protective systems weaken, leaving the eye vulnerable to damaging stress. Free oxygen radicals damage proteins, which clump together and form fatty deposits called drusen, the main warning sign of dry AMD.

The team's innovation targets these problems at the source. The gentle heating activates heat shock proteins, which help damaged proteins fold back into their correct shape. It also triggers autophagy, a cellular cleanup process that won a Nobel Prize in 2016 when scientist Yoshinori Ohsumi revealed how it works.

The treatment requires precise temperature control. The tissue must stay below 45 degrees Celsius to avoid damage, so the researchers developed a system that heats and monitors temperature simultaneously in real time.

Testing in mice and pigs showed the approach successfully activates both protective systems in retinal tissue. Human trials are scheduled to begin in Finland this spring, starting with safety testing before moving on to effectiveness studies.

The Bright Side

This research represents a fundamental shift in how doctors think about dry AMD. Instead of trying to repair damage after vision loss has advanced, the treatment helps vulnerable cells defend themselves early. It's like maintaining a car before it breaks down rather than waiting for a costly repair.

The approach won't be a one-time fix. Koskelainen notes the protective response begins declining within days, so patients would likely need repeated treatments to maintain the benefits, similar to regular maintenance therapy.

For millions watching their vision slowly fade, this new strategy offers something that's been missing: genuine hope for intervention before blindness takes hold.